Dulaglutide dosage in published studies and labels

These are the doses used for Dulaglutide in FDA labelling and published clinical studies, reported as each source states them, one row per regimen. They describe what was studied or approved for a specific population. They are not a recommendation, and none of them is a dose for any individual.

Research and educational reference only. This is not medical advice, and no figure on this page is a dosing recommendation.

Last checked against primary sources: November 7, 2026

Studied regimens and sources

Dulaglutide has an FDA-approved human dosage. Trulicity for adults with type 2 diabetes starts at 0.75 mg once weekly under the skin, can go to 1.5 mg after 4 weeks, and then up in 1.5 mg steps to a maximum of 4.5 mg once weekly. For children aged 10 and over with type 2 diabetes the maximum is 1.5 mg once weekly.

FDA Approved

Dosage evidence summary for Dulaglutide
Human dosing established	Yes
Studied dose range	0.75–4.5 mg once weekly (maximum 1.5 mg in children)
Route	Subcutaneous
Frequency	Once weekly, any time of day, with or without food
Duration studied	Continuous
Titration	0.75 mg weekly to start; after 4 weeks 1.5 mg; then 3 mg and 4.5 mg, each after at least 4 weeks on the current dose.
Evidence level	FDA Approved
Last reviewed	2026-11-07

Research-reported dosing

Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.

Research-reported dosing for Dulaglutide, one row per studied regimen
Study / context	Population	Dose	Route	Frequency	Duration	Outcome studied	Source
FDA label — Trulicity, type 2 diabetes in adultsFDA-approved label · FDA prescribing information	Adults with type 2 diabetes mellitus	Start 0.75 mg; 1.5 mg after 4 weeks; then 1.5 mg steps every 4 weeks or more; maximum 4.5 mg	Subcutaneous, abdomen, thigh or upper arm	Once weekly	Continuous, with diet and exercise	Glycemic control	TRULICITY (dulaglutide) injection — FDA prescribing information, DailyMed
FDA label — Trulicity, type 2 diabetes in childrenFDA-approved label · FDA prescribing information	Children aged 10 years and older with type 2 diabetes mellitus	Start 0.75 mg; maximum 1.5 mg after at least 4 weeks	Subcutaneous	Once weekly	Continuous	Glycemic control	TRULICITY (dulaglutide) injection — FDA prescribing information, DailyMed
FDA label — Trulicity, cardiovascular risk reductionFDA-approved label · FDA prescribing information	Adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors	Same adult dosing: 0.75 mg to start, up to 4.5 mg	Subcutaneous	Once weekly	Continuous	Lower risk of major adverse cardiovascular events	TRULICITY (dulaglutide) injection — FDA prescribing information, DailyMed

Where sources disagree

The adult and pediatric ceilings differ: 4.5 mg once weekly for adults and 1.5 mg once weekly for children aged 10 and over.
Trulicity carries a boxed warning about thyroid C-cell tumors seen in rats. It must not be used by people with a personal or family history of medullary thyroid carcinoma or with MEN 2.